S2-E7 – The Newer Diabetes Drugs and Patients with NASH

The Newer Diabetes Drugs and Patients with NASH
Jörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that GLP-1 receptor agonists like semaglutide and SGLT-2 inhibitors like Jardiance in treating NASH patients.

Over the next couple of years, we are likely to see improvements in our ability to diagnose and track NASH patients but no new medicines to treat them. On this podcast, Jörn Schattenberg reviews data on the role that two relatively recent classes of diabetes drugs, GLP-1s (semaglutide) and SGLT-2s (Jardiance), can play in NASH and NAFLD therapy. Wayne Eskridge discusses implications for patients. while Louise Campbell and Roger Green elaborate opportunities and challenges in educating patients and health care professionals to think about liver and diabetes in a more integrated way. This episode presents perspectives and concepts with value today.

Experience Nudge Learning! Interested in a new way of learning?